RRAJASTHAN NEWS 24News that matters

Home / USA / Company Earnings and Healthcare

BUSINESS · HEALTHCARE EARNINGS

Moderna Reports $162 Million Q3 Profit and Raises Its 2026 Revenue Outlook

Editorial illustration of a vaccine vial, laboratory equipment and an upward company earnings chart.
Editorial illustration. Editorial illustration of a vaccine vial, laboratory equipment and an upward company earnings chart.

Moderna reported third-quarter revenue of about $1.3 billion and net income of $162 million, compared with a loss a year earlier. The company raised its 2026 revenue-growth outlook after stronger international COVID vaccine demand.

CAMBRIDGE, MASSACHUSETTS, November 6, 2026: Moderna reported third-quarter revenue of about $1.3 billion and net income of $162 million, compared with a loss a year earlier. The company raised its 2026 revenue-growth outlook after stronger international COVID vaccine demand.

Moderna reported third-quarter 2026 revenue of about $1.3 billion, up from $1.016 billion in the same period last year. The biotechnology company posted net income of $162 million, compared with a net loss of about $200 million in the third quarter of 2025.

International vaccine demand lifted sales

Moderna said stronger COVID vaccine demand in international markets and payments from partnerships helped drive the improvement. The results show a stronger quarter, but they do not mean the company has eliminated its dependence on vaccine demand or seasonal sales patterns.

Company raises its 2026 outlook

Moderna now expects full-year 2026 revenue growth of 15% to 25%, compared with its previous outlook of growth of up to 10%. That range is management guidance, not a guarantee. Actual revenue will depend on demand, competition, partnerships, regulatory decisions and delivery timing.

Pipeline progress and risks

Moderna highlighted late-stage results for its experimental personalized melanoma vaccine candidate intismeran, used with Merck’s Keytruda. Reuters reported that the combination cut the risk of recurrence or death by 42% in the study. The company said it is working to submit a U.S. marketing application this year, with a potential commercial launch targeted for 2027. The candidate is not yet an approved treatment.

Moderna also said it would not add another cohort to its experimental norovirus vaccine study this season after an interim analysis failed to meet the statistical threshold for early success.

What investors should watch

Investors will be looking for evidence that Moderna can diversify revenue beyond COVID vaccines, turn clinical progress into approved products and maintain cash discipline. A profitable quarter and a higher forecast are positive company results, but they do not remove clinical, regulatory or commercial risks.

Sources and further reading

Editorial note: Quarterly results are reported company figures. The 2026 revenue range is management guidance, and clinical-trial results are not the same as regulatory approval.

Related coverage: Latest U.S. news · Business and finance news

← Back to U.S. news · Business and finance coverage